



# Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects

Merel Jacobs <sup>1</sup>, Hannelore P. Van Eeckhoutte<sup>1</sup>, Sara R.A. Wijnant <sup>1,2,3</sup>, Wim Janssens <sup>4</sup>, Guy F. Joos <sup>1</sup>, Guy G. Brusselle <sup>1,2,5</sup> and Ken R. Bracke<sup>1</sup>

**Affiliations:** <sup>1</sup>Laboratory for Translational Research in Obstructive Pulmonary Diseases, Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium. <sup>2</sup>Dept of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands. <sup>3</sup>Dept of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. <sup>4</sup>Respiratory Division and Rehabilitation, University Hospital Leuven, Leuven, Belgium. <sup>5</sup>Dept of Respiratory Diseases, Erasmus Medical Center, Rotterdam, The Netherlands.

**Correspondence:** Ken R. Bracke, Dept of Respiratory Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium. E-mail: ken.bracke@UGent.be

@ERSpublications

**This study demonstrates increased protein levels of ACE2 in alveolar and bronchial epithelium of smokers and subjects with COPD, which might facilitate host cell entry of SARS-CoV-2** <https://bit.ly/2ZazOrd>

**Cite this article as:** Jacobs M, Van Eeckhoutte HP, Wijnant SRA, *et al.* Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. *Eur Respir J* 2020; 56: 2002378 [<https://doi.org/10.1183/13993003.02378-2020>].

This single-page version can be shared freely online.

*To the Editor:*

Angiotensin-converting enzyme 2 (ACE2) has been identified as the cell entry receptor used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1, 2]. Importantly, smokers and patients with COPD are at an increased risk of severe complications and a higher mortality upon SARS-CoV-2 infection [3]. We hypothesised that ACE2 expression is increased in lungs of smokers and patients with COPD, which may at least partially explain their higher risk of a more severe course of coronavirus disease 2019 (COVID-19). Therefore, we aimed to investigate the expression of ACE2 on both mRNA and protein level in a large number of lung tissue specimens of well-phenotyped subjects, including never-smokers, current smokers without airflow limitation, and patients with COPD.